{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T22:43:30Z","timestamp":1775688210652,"version":"3.50.1"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T00:00:00Z","timestamp":1654732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>There is a paucity of data on the use of intravenous magnesium sulfate infusion in children with refractory status asthmaticus. The purpose of this study was to evaluate the efficacy and safety of prolonged magnesium sulfate infusion as an advanced therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a single center retrospective study of children admitted to our pediatric intensive care unit (PICU) with status asthmaticus requiring continuous albuterol. Treatment group included patients receiving magnesium for \u22654 h and control group included those on other therapies only. Patients were matched 1:4 based on age, sex, obesity, pediatric index of mortality III and pediatric risk of mortality III scores. Primary outcomes included PICU length of stay (LOS) and mechanical ventilation (MV) requirement. Secondary outcomes included mortality, extracorporeal membrane oxygenation (ECMO) requirement, analyses of factors associated with PICU LOS and MV requirement and safety of magnesium infusion. Logistic and linear regressions were employed to determine factors associated with MV requirement and PICU LOS, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Treatment and control groups included 27 and 108 patients, respectively. Median initial infusion rate was 15 mg\/kg\/hour, with median duration of 28 h. There was no difference in the MV requirement between the treatment and control groups [7 (25.9%) vs. 20 patients (18.5%), <jats:italic>p<\/jats:italic> = 0.39]. Median PICU LOS and ECMO use were significantly higher in treatment vs. control group [(3.63 vs. 1.09 days, <jats:italic>p<\/jats:italic> &amp;lt; 0.01) and (11.1 vs. 0%, <jats:italic>p<\/jats:italic> &amp;lt; 0.01), respectively]. No mortality difference was noted. On regression analysis, patients receiving ketamine and higher prednisone equivalent dosing had higher odds of MV requirement [OR 19.29 (95% CI 5.40\u201368.88), <jats:italic>p<\/jats:italic> &amp;lt; 0.01 and 1.099 (95% CI 1.03\u20131.17), <jats:italic>p<\/jats:italic> &amp;lt; 0.01, respectively]. Each mg\/kg increase in prednisone equivalent dosing corresponded to an increase in PICU LOS by 0.13 days (95% CI 0.096\u20130.160, <jats:italic>p<\/jats:italic> &amp;lt; 0.01). Magnesium infusions were not associated with lower MV requirement or lower PICU LOS after controlling for covariates. Fourteen (51.9%) patients in the treatment group had an adverse event, hypotension being the most common.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Magnesium sulfate infusions were not associated with MV requirement, PICU LOS or mortality.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2022.860921","type":"journal-article","created":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T04:36:01Z","timestamp":1654749361000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and Safety of Prolonged Magnesium Sulfate Infusions in Children With Refractory Status Asthmaticus"],"prefix":"10.3389","volume":"10","author":[{"given":"Khalid W.","family":"Taher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter N.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamie L.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen B.","family":"Neely","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neha","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,6,9]]},"reference":[{"key":"B1","first-page":"1","article-title":"Trends in asthma prevalence, health care use, and mortality in the United States, 2001-2010","author":"Akinbami","year":"2012","journal-title":"NCHS Data Brief."},{"key":"B2","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.1016\/j.jaci.2007.09.029","article-title":"Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007","volume":"120","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"B3","unstructured":"Global Strategy for Asthma Management Prevention2021"},{"key":"B4","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s00228-016-2165-3","article-title":"Clinical pharmacokinetics of magnesium sulfate in the treatment of children with severe acute asthma","volume":"73","author":"Rower","year":"2017","journal-title":"Eur J Clin Pharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"88","DOI":"10.5863\/1551-6776-18.2.88","article-title":"Severe acute asthma exacerbation in children: a stepwise approach for escalating therapy in a pediatric intensive care unit","volume":"18","author":"Nievas","year":"2013","journal-title":"J Pediatr Pharmacol Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1002\/ppul.24013","article-title":"The effectiveness of magnesium sulfate for status asthmaticus outside the intensive care setting","volume":"53","author":"DeSanti","year":"2018","journal-title":"Pediatr Pulmonol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1159\/000506595","article-title":"Efficacy of magnesium sulfate treatment in children with acute asthma","volume":"29","author":"\u00d6zdemir","year":"2020","journal-title":"Med Princ Pract."},{"key":"B8","doi-asserted-by":"publisher","first-page":"150","DOI":"10.5863\/1551-6776-17.2.150","article-title":"Feasibility of short-term infusion of magnesium sulfate in pediatric patients with status asthmaticus","volume":"17","author":"Irazuzta","year":"2012","journal-title":"J Pediatr Pharmacol Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s00134-012-2734-6","article-title":"High-dose magnesium sulfate infusion protocol for status asthmaticus: a safety and pharmacokinetics cohort study","volume":"39","author":"Egelund","year":"2013","journal-title":"Intensive Care Med."},{"key":"B10","doi-asserted-by":"publisher","first-page":"233","DOI":"10.5863\/1551-6776-21.3.233","article-title":"Comparison of two high-dose magnesium infusion regimens in the treatment of status asthmaticus","volume":"21","author":"Vaiyani","year":"2016","journal-title":"J Pediatr Pharmacol Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1097\/PCC.0000000000000581","article-title":"High-dose magnesium sulfate infusion for severe asthma in the emergency department: efficacy study","volume":"17","author":"Irazuzta","year":"2016","journal-title":"Pediatr Crit Care Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1053\/jcrc.2002.36759","article-title":"Magnesium sulfate administered via continuous intravenous infusion in pediatric patients with refractory wheezing","volume":"17","author":"Glover","year":"2002","journal-title":"J Crit Care."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1002\/ppul.24499","article-title":"Safety of prolonged magnesium sulfate infusions during treatment for severe pediatric status asthmaticus","volume":"54","author":"Graff","year":"2019","journal-title":"Pediatr Pulmonol."},{"key":"B14","unstructured":"Los Angeles, CALLCVirtual Pediatric Systems (VPS)2022"},{"key":"B15","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1542\/peds.2007-0409","article-title":"Childhood overweight increases hospital admission rates for asthma","volume":"120","author":"Carroll","year":"2007","journal-title":"Pediatrics."},{"key":"B16","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1097\/01.PCC.0000243749.14555.E8","article-title":"Childhood obesity increases duration of therapy during severe asthma exacerbations","volume":"7","author":"Carroll","year":"2006","journal-title":"Pediatr Crit Care Med."},{"key":"B17","unstructured":"BMI Percentile Calculator for Child and Teen"},{"key":"B18","unstructured":"GenevaWorld Health OrganizationWHO Child Growth Standards: Length\/Height-for-Age, Weight-for-Age, Weight-for-Length, Weight-for-Height Body Mass Index-for-Age: Methods Development2006"},{"key":"B19","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/1710-1492-9-30","article-title":"A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Allergy Asthma Clin Immunol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1161\/01.CIR.102.suppl_1.I-291","article-title":"CPR and first aid emergency cardiovascular care. part 10: pediatric advanced life support","volume":"102","year":"2000","journal-title":"Circulation."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/02770903.2021.1941085","article-title":"Noninvasive ventilation use in pediatric status asthmaticus","author":"Usala","year":"2021","journal-title":"J Asthma"},{"key":"B22","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jpeds.2012.02.041","article-title":"Fatal and near-fatal asthma in children: the critical care perspective","volume":"161","author":"Newth","year":"2012","journal-title":"J Pediatr"},{"key":"B23","doi-asserted-by":"publisher","first-page":"R29","DOI":"10.1186\/cc7735","article-title":"Experience with use of extracorporeal life support for severe respiratory status asthmaticus in children","volume":"13","author":"Hebbar","year":"2009","journal-title":"Crit Care."},{"key":"B24","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1002\/ppul.24616","article-title":"winter to remember! Extracorporeal membrane oxygenation for life-threatening asthma in children: a case series and review of literature","volume":"55","author":"Medar","year":"2020","journal-title":"Pediatr Pulmonol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1080\/02770903.2019.1565826","article-title":"Status asthmaticus requiring extracorporeal membrane oxygenation associated with rhinovirus infection","volume":"57","author":"Lauren","year":"2019","journal-title":"J Asthma."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1542\/peds.83.6.1023","article-title":"Severe acute asthma in a pediatric intensive care unit: six years' experience","volume":"83","author":"Stein","year":"1989","journal-title":"Pediatrics."},{"key":"B27","doi-asserted-by":"publisher","first-page":"635","DOI":"10.4187\/respcare.07944","article-title":"S Dhaliwal D, Fischer GA, Davey CS, Gupta S. Implementation of a critical asthma protocol in a pediatric ICU","volume":"66","author":"Kucher","year":"2021","journal-title":"Respir Care."},{"key":"B28","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/PCC.0b013e31828a7451","article-title":"Corticosteroid therapy in critically ill pediatric asthmatic patients","volume":"14","author":"Giuliano JS","year":"2013","journal-title":"Pediatr Crit Care Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/s13054-018-2111-0","article-title":"Corticosteroid use and intensive care unit-acquired weakness: a systematic review and meta-analysis","volume":"22","author":"Yang","year":"2018","journal-title":"Crit Care."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1002\/ppul.24821","article-title":"Terbutaline and aminophylline as second-line therapies for status asthmaticus in the pediatric intensive care unit","volume":"55","author":"Stulce","year":"2020","journal-title":"Pediatr Pulmonol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1177\/08850666211026550","article-title":"Heliox for pediatric critical asthma: a multicenter, retrospective, registry-based descriptive study","volume":"37","author":"Lew","year":"2022","journal-title":"J Intens Care Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1177\/1060028015626932","article-title":"Ketamine continuous infusions in critically ill infants and children","volume":"50","author":"Golding","year":"2016","journal-title":"Ann Pharmacother."},{"key":"B33","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1097\/00006565-199408000-00004","article-title":"Safety and efficacy of magnesium sulfate infusions in children with status asthmaticus","volume":"10","author":"Pabon","year":"1994","journal-title":"Pediatr Emerg Care."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.860921\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T04:36:07Z","timestamp":1654749367000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2022.860921\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,9]]},"references-count":33,"alternative-id":["10.3389\/fped.2022.860921"],"URL":"https:\/\/doi.org\/10.3389\/fped.2022.860921","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,9]]},"article-number":"860921"}}